Prospect: Information for the Patient
Quetiapina Viatris 200 mg prolonged-release tablets EFG
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
1.What is Quetiapina Viatris and for what it is used
2.What you need to know before starting to take Quetiapina Viatris
3.How to take Quetiapina Viatris
4.Possible adverse effects
5.Storage of Quetiapina Viatris
6.Contents of the package and additional information
Quetiapina Viatris contains a substance called quetiapina. It belongs to a group of medications called antipsychotics. Quetiapina may be used to treat several conditions, such as:
When using quetiapina to treat major depressive episodes in major depressive disorder, it will be taken in addition to another medication that is being used to treat this condition.
Your doctor may continue prescribing quetiapina even when you are feeling better.
Do not take Quetiapina Viatris:
-If you are allergic to quetiapine or any of the other ingredients of this medication (listed in section 6).
-If you are taking any of the following medications:
‑Some HIV medications.
‑Azole antifungals (for fungal infections).
‑Erythromycin or clarithromycin (for infections).
‑Nefazodone (for depression).
Do not take quetiapine if the above applies to you. If in doubt, consult your doctor or pharmacist before taking quetiapine.
Warnings and precautions
Consult your doctor or pharmacist before starting this medication if:
Inform your doctor immediately if you experience any of the following after taking quetiapine:
These conditions may be caused by this type of medication.
Inform your doctor as soon as possible if you have:
Thoughts of suicide and worsening of depression
If you are depressed, you may sometimes think about harming yourself or committing suicide. These thoughts may increase when starting treatment, as all these medications take time to take effect, usually around two weeks, but sometimes longer. These thoughts may also increase if you stop taking your medication abruptly.
You may be more likely to think this way if you are a young adult. Information from clinical trials has shown an increased risk of thoughts of suicide and/or suicidal behavior in young adults under 25 with depression.
If you ever think about harming yourself or committing suicide, contact your doctor or go to the hospital immediately. It may help to tell a close family member or friend that you are depressed and ask them to read this leaflet. You can ask them to alert you if they think your depression is worsening or if they are concerned about changes in your behavior.
Severe skin reactions (SCARs)
Very rarely, severe skin reactions (SCARs) have been reported with the use of this medication, which may put your life at risk or be fatal. These typically manifest as:
If you develop these symptoms, stop using this medication and contact your doctor or seek medical attention immediately.
Weight gain
Weight gain has been observed in patients taking quetiapine. You and your doctor should monitor your weight regularly.
Children and adolescents
Quetiapine should not be used in children under 18 years old.
Other medications and Quetiapina Viatris
Inform your doctor if you are taking, have taken recently, or may need to take any other medication, including those purchased without a prescription and herbal remedies.
Do not take quetiapine if you are using any of the following medications:
Inform your doctor if you are taking any of the following medications:
Consult your doctor before stopping any of your medications.
Quetiapina Viatris with food, drinks, and alcohol
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
Do not take quetiapine during pregnancy, unless you have consulted your doctor. Do not take quetiapine if you are breastfeeding.
The following symptoms, which may require withdrawal, may appear in newborns of mothers who have used quetiapine in the last trimester (last three months of pregnancy): tremors, rigidity, and/or muscle weakness, drowsiness, agitation, respiratory problems, and feeding difficulties. If your baby experiences any of these symptoms, contact your doctor.
Driving and operating machinery
These tablets may make you feel drowsy. Do not drive or operate tools or machinery until you know how the tablets affect you.
Effect on urine drug detection tests
If you are undergoing a urine drug detection test, taking quetiapine may produce positive results for methadone or certain antidepressant medications called tricyclic antidepressants (TCA) when using certain analysis methods, although you are not taking methadone or TCA. If this occurs, a more specific test may be performed.
Quetiapina Viatris contains sodium
This medication contains less than 23 mg of sodium (1mmol) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions provided by your doctor for this medication. Consult your doctor or pharmacist if you have any doubts. Your doctor will determine your initial dose. The maintenance dose (daily dose) will depend on your condition and needs, but will usually be between 150 mg and 800 mg.
Liver problems
If you have liver problems, your doctor may change your dose.
Older adults
If you are an older adult, your doctor may change your dose.
Use in children and adolescents
Quetiapina should not be used by individuals under 18 years of age.
If you take more Quetiapina Viatris than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you take more quetiapina than prescribed by your doctor, you may feel drowsy, feel dizzy, and experience abnormal heartbeats.
If you forget to take a dose of Quetiapina Viatris
If you forget to take a dose, take it as soon as you remember. If it is almost time to take the next dose, wait until then. Do not take a double dose to make up for the missed dose.
If you interrupt treatment with Quetiapina Viatris
If you stop taking quetiapina abruptly, you may be unable to sleep (insomnia), feel nausea (urge to vomit), or experience headaches, diarrhea, vomiting, dizziness, or irritability. Your doctor may suggest reducing the dose gradually before stopping treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. If you experience side effects, consult your doctor or pharmacist, even if they are side effects that do not appear in this leaflet.
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
Frequency not known (cannot be estimated from available data)
The class of medicines to which Quetiapine Viatris belongs may cause heart rhythm problems, which can be serious and in severe cases may be fatal.
Some side effects are only observed when a blood test is performed. These include changes in the amount of certain fats (triglycerides and total cholesterol) or sugar in the blood, changes in the amount of thyroid hormones in the blood, increased liver enzymes, decreases in the number of certain types of blood cells, decreases in the amount of red blood cells, increases in creatine phosphokinase (a substance found in muscles) in the blood, decreases in the amount of sodium in the blood, and increases in the amount of prolactin hormone in the blood.
Your doctor may ask you to have blood tests from time to time.
Side effects in children and adolescents
The same side effects that may occur in adults may also occur in children and adolescents.
The following side effects have been observed more frequently in children and adolescents or have not been observed in adults:
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 patients):
Reporting of side effects
If you experience side effects, consult your doctor or pharmacist, even if they are side effects that do not appear in this leaflet. You can also report any side effects directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Do not use this medication after the expiration date that appears on the box after "CAD" or “EXP”. The expiration date is the last day of the month indicated.
Store in the outer packaging to protect it from moisture.
Do not dispose of medications through drains or trash. Deposit containers and unused medications at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of containers and unused medications. By doing so, you will help protect the environment.
Composition of Quetiapina Viatris
Tablet core: hypromellose 2910 (E-464), hypromellose 2208 (E-464), microcrystalline cellulose (E-460i), anhydrous sodium citrate (see section 2 “Quetiapina Viatris contains sodium”), magnesium stearate (E-572).
Tablet coating: titanium dioxide (E-171), hypromellose 2910 (E-464), macrogol/PEG 400, polisorbate 80, yellow iron oxide (E-172), red iron oxide (E-172).
Appearance of the product and contents of the package
Quetiapina Viatris is presented in the form of film-coated, biconvex, oblong, yellow tablets, marked with "Q 200" on one side.
This medicine is available in plastic bottles containing 60 prolonged-release tablets, or blister strips in cardboard boxes, which contain:
Continuous blisters – Aluminum blisters in a cardboard box with 10, 30, 60, and 100 prolonged-release tablets.
Perforated single-dose blisters – Aluminum blisters in a cardboard box with 10, 30, 60, and 100 prolonged-release tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Responsible for manufacturing
Mylan Hungary Kft
H-2900 Komárom Mylan utca 1
Hungary
or
Merckle GmbH
Ludwig-Merckle-Straße 3, 89143 Blaubeuren
Germany
or
McDermott Laboratories t/a Gerard Laboratories t/a Mylan Dublin
Unit 35/36, Baldoyle Industrial Estate, Grange Road
Dublin 13
Ireland
Further information about this medicine can be obtained by contacting the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.U.
C/ General Aranaz, 86
28027 - Madrid
Spain
This medicine is authorized in the member states of the European Economic Area with the following names:
SpainQuetiapinaViatris200 mg prolonged-release tablets EFG
GreeceQuetiapine/Mylan Prolonged Release Tablets 200 mg/TAB
ItalyQuetiapina Mylan
PortugalQuetiapina Mylan
United KingdomAlaquet XL 200 mg prolonged-release tablets
Czech RepublicQuetiapin Mylan 200 mg, tablety's prodlouženým uvolnováním
Last review date of this leaflet:July 2024
Further detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) https://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.